DJIA 18,214.42 -10.15 -0.06%
NASDAQ 4,987.89 20.75 0.42%
S&P 500 2,110.74 -3.12 -0.15%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)



company name or ticker

Orexigen's Q4 Results Disappoint, But Contrave Is Gaining Market Share

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst B

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch

Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.

VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog

Why Vivus Inc Plummeted Today

Vivus Inc shares tanked today following results that failed to impress.

JPM Securities Picks Through Biotech News For Winners

Wednesday's #PreMarket Movers: Hewlett-Packard, Dreamworks Animation Trending Lower

VIVUS' (VVUS) CEO Seth Fischer on Q4 2014 Results -- Earnings Call Transcript

UPDATE: VIVUS Posts Q4 Loss

Vivus (VVUS) Q4 2014 Results - Earnings Call Webcast

See More Articles...